SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Link Biologics Completes IND-Enabling Preclinical Programme for LB001

Link Biologics says it completed IND-enabling preclinical work for its dry eye disease therapy LB001.

Related stories